Evidence map›Paper›PMID 32995896›Full record

ReviewHNO2020

[Liquid biopsy-a possible key player in immuno-oncology].

M Wallesch, M Wirth, B Wollenberg

Abstract readReview
PubMed Publisher
In one paragraph

Review in HNO, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 61% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

M WalleschKlinik und Poliklinik für Hals‑, Nasen- und Ohren Heilkunde des Klinikums rechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675, München, Deutschland.
M WirthKlinik und Poliklinik für Hals‑, Nasen- und Ohren Heilkunde des Klinikums rechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675, München, Deutschland.
B WollenbergKlinik und Poliklinik für Hals‑, Nasen- und Ohren Heilkunde des Klinikums rechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675, München, Deutschland. barbara.wollenberg@tum.de.
Technical University of Munich · DEKlinik und Poliklinik für Hals-Nasen-Ohren-Heilkunde · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundClinical application of immune checkpoint inhibitors (ICI), whether as monotherapy or in combination with established methods, is revolutionizing treatment of head and neck cancer. However, this change in therapeutic concepts requires reevaluation and further development of predictive and prognostic markers, since the survival rates for advanced and particularly human papillomavirus (HPV)-negative disease remain poor. MATERIALS AND

methodsA selective literature review was performed in PubMed. Literature found with the keywords "cytodiagnostics, circulating tumor cells, liquid biopsy, cfDNA, exosomes" in combination with "head and neck cancer" and/or "immune checkpoint inhibitor therapy" published until March 2020 was included. The articles were selected for their relevance for the current study by the authors.

resultsThis work provides a review of the current literature and indicates possible applications in the field of head and neck cancers. Liquid biopsy refers to the analysis of circulating tumor cells or of tumor genetic material in body fluids. This minimally invasive analysis can support therapeutic decisions and enable a personalized approach to treating head and neck cancer. DISCUSSION: Before any of these approaches can be established in clinical routine, long-term data and standardization of the methods for isolating and analyzing the markers are needed.

Indexed as

Head and Neck NeoplasmsNeoplastic Cells, CirculatingBiomarkers, TumorHumansLiquid BiopsyMedical OncologyBiomarkers, TumorCirculating tumor cellsCytodiagnosisExosomesHead and neck neoplasmsImmunotherapy

Identifiers

PMID32995896
OpenAlexW3090065480

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.